Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Merus regains some lost pride while Bicycle rides to even greater heights.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.